OQROGet OQRO Pro
Insider trade

Regeneron Pharmaceuticals (REGN)EVP Commercial sold ~$845K

Marion Mccourt, EVP Commercial at Regeneron Pharmaceuticals, sold ~$845K of Regeneron Pharmaceuticals shares.

~$845K
Approx. value · 1,000 sh @ $844.61
13K
Holds after · shares reported
Traded
Nov 1, 2024
Filed
Nov 5, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 12, 2024FDAFDA drug approval: Dupixent
  2. Sep 27, 2024FDAFDA drug approval: Dupixent
  3. Oct 1, 2024Insider · 2 peopleInsiders: 18 sales (~$1.2M)
  4. Oct 15, 2024CongressDisclosed sale of REGN — reported range $1,001 - $15,000
  5. Oct 23, 2024CongressDisclosed partial sale of REGN — reported range $1,001 - $15,000
  6. Nov 1, 2024 · this disclosureInsiderOfficer sold ~$845K of REGN shares in the open market

What came next

  1. Nov 1, 2024CongressDisclosed partial sale of REGN — reported range $1,001 - $15,000
  2. Nov 13, 2024CongressDisclosed sale of REGN — reported range $15,001 - $50,000
  3. Nov 19, 2024CongressDisclosed partial sale of REGN — reported range $1,001 - $15,000
  4. Nov 29, 2024CongressDisclosed partial sale of REGN — reported range $1,001 - $15,000
  5. Jan 7, 2025Court · District Court, S.D. New YorkSecurities lawsuit filed: In re Regeneron Pharmaceuticals, Inc. Securities Litigation
  6. Jan 15, 2025CongressDisclosed purchase of REGN — reported range $1,001 - $15,000
  7. Jan 24, 2025CongressDisclosed sale of REGN — reported range $1,001 - $15,000
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Regeneron Pharmaceuticals

For Regeneron Pharmaceuticals, OQRO holds 8 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 31 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its REGN page.

Other recent filings by Marion Mccourt, EVP Commercial

The full history of Marion Mccourt, EVP Commercial is on the profile page.

How this filing works

Other disclosures at Regeneron Pharmaceuticals

Everything OQRO holds on this company is on its REGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data